# Understanding Viral Myocarditis: A Complete Guide to Diagnosis and Treatment Myocarditis is an inflammatory disease of the heart muscle that remains an important and often unrecognized cause of dilated cardiomyopathy (a weakened and enlarged heart) worldwide. This comprehensive review from Mayo Clinic physicians explains how viral infections trigger myocarditis, describes modern diagnostic tools such as cardiac MRI and endomyocardial biopsy, and outlines treatment strategies ranging from standard heart failure medications to mechanical circulatory support. The review includes a detailed patient case, data on the changing landscape of viruses that cause myocarditis, and evidence-based recommendations for diagnosis and therapy. # Understanding Viral Myocarditis: A Complete Guide to Diagnosis and Treatment ## Table of Contents - Key Points - Introduction: What Is Myocarditis? - A Real Patient Story: The Case of a 19-Year-Old Woman - Causes and How the Disease Develops - Symptoms and Diagnosis: What Patients Should Know - Advanced Imaging: The Role of Cardiac MRI - Endomyocardial Biopsy: When Is It Needed? - Treatment Options for Viral Myocarditis - Mechanical Circulatory Support for Severe Cases - Antiviral and Immunosuppressive Therapy - Prognosis: What to Expect - Study Limitations - Recommendations for Patients - Frequently Asked Questions - Source Information ## Key Points - Myocarditis is inflammation of the heart muscle and a common cause of dilated cardiomyopathy, but it often goes undiagnosed because symptoms can be vague. - In one European study, 72% of myocarditis patients had shortness of breath, 32% had chest pain, and 18% had arrhythmias; some are asymptomatic. - Diagnosis may include troponin blood tests, ECG, echocardiography, cardiac MRI, and endomyocardial biopsy; troponin levels are normal in many patients. - Cardiac MRI can detect inflammation and scarring; in a 32-patient study, 88% had contrast enhancement and 90% of biopsied areas showed active myocarditis. - Standard heart failure drugs (ACE inhibitors, beta-blockers, aldosterone antagonists, diuretics) are the mainstay of treatment; immunosuppression is not generally helpful for acute myocarditis. ## Introduction: What Is Myocarditis? Myocarditis is defined as inflammation of the heart muscle (the myocardium) that can be identified through clinical signs or by examining heart tissue under a microscope. It is an important cause of dilated cardiomyopathy (DCM), a condition in which the heart becomes enlarged, weakened, and unable to pump blood effectively. Worldwide, myocarditis is recognized as a major contributor to heart failure, yet it often goes undiagnosed because its symptoms can be vague or even absent. The authors of this review set out to provide a contemporary, evidence-based approach to evaluating and treating patients with suspected myocarditis. They analyzed English-language publications in PubMed and references from relevant articles published between January 1, 1985, and August 5, 2008. The main keywords searched were myocarditis, dilated cardiomyopathy, endomyocardial biopsy, cardiac magnetic resonance imaging, and immunotherapy. Recent developments have improved the ability to diagnose this condition. These include refined histologic criteria (more precise ways to examine tissue samples) and the use of cardiac magnetic resonance imaging (MRI), a noninvasive imaging technique that can detect inflammation and scarring in the heart muscle. One striking statistic highlights the importance of this disease: research suggests that myocarditis is the cause of sudden cardiac death in **8.6% of cases** and is identified in up to **9% of routine postmortem examinations**. Most studies also report a slight male predominance. ## A Real Patient Story: The Case of a 19-Year-Old Woman To illustrate how viral myocarditis can present and progress, the authors describe the case of a 19-year-old previously healthy woman. She visited her primary care physician complaining of increasing shortness of breath on exertion that had developed over 2 to 3 days. Notably, she had experienced an upper respiratory tract infection 3 weeks earlier—a common precursor to viral myocarditis. A chest X-ray showed mild cardiac enlargement, and a subsequent echocardiogram (ultrasound of the heart) revealed a small circumferential pericardial effusion (fluid around the heart). She was initially treated with ibuprofen for presumed postviral pericarditis (inflammation of the sac surrounding the heart). Two days later, the situation took a dramatic turn. The patient was found unconscious in her shower. An electrocardiogram (ECG) revealed diffuse ST-segment elevation throughout the precordial leads, along with 1.0-mm PR-segment depression in leads I and II—findings that can mimic a heart attack. She underwent immediate coronary catheterization, which showed normal coronary arteries, ruling out coronary artery disease as the cause. She was transferred to a tertiary referral center for further evaluation. On arrival, she was intubated (on a breathing tube) and sedated, with a heart rate of **125 beats per minute** and a blood pressure of **94/60 mm Hg**—signs of hemodynamic compromise (the body's organs not receiving adequate blood flow). Physical examination revealed an S3 gallop (an abnormal heart sound associated with heart failure), elevated jugular venous pressure at 8 cm H2O, and scattered crackles on lung examination. An echocardiogram showed a **left ventricular ejection fraction (LVEF) of 15% to 20%**—a severely reduced pumping function (normal is typically 55% or higher)—with generalized hypokinesis (widespread reduced wall motion) and a small pericardial effusion. Laboratory findings were striking: - White blood cell count: **27.2 × 109/L** (reference range: 3.5–10.5 × 109/L), indicating a significant inflammatory response - Creatinine kinase–MB isoenzyme (CK-MB) fraction: **22 ng/mL** (reference: <6.2 ng/mL), a marker of heart muscle damage - Troponin T level: **0.9 ng/mL** (reference: <0.01 ng/mL), another highly sensitive marker of cardiac injury An emergent right heart catheterization with endomyocardial biopsy was performed. The biopsy specimen showed **active lymphocytic myocarditis**—meaning the heart muscle was infiltrated with lymphocytes, a type of white blood cell involved in the immune response. Inotropic support (medications to strengthen heart contractions) was initiated with dobutamine, and gentle afterload reduction (reducing the resistance the heart must pump against) was started with nitroglycerin. The patient's recovery was remarkable. She was weaned from hemodynamic support and extubated (taken off the breathing tube). Low doses of a β-blocker and an angiotensin-converting enzyme (ACE) inhibitor were initiated—standard heart failure medications. At her **6-week follow-up, her LVEF had improved to 66%**, which is within the normal range. Subsequent analysis of her endomyocardial tissue using polymerase chain reaction (PCR), a molecular technique that detects genetic material, was **positive for Epstein-Barr virus**, confirming the viral cause of her myocarditis. ## Causes and How the Disease Develops The pathogenesis of myocarditis has been studied extensively in animal models. Viruses enter cardiac myocytes (heart muscle cells) and macrophages (immune cells) through specific receptors, triggering a cytotoxic (cell-damaging) effect. The spectrum of viruses known to cause myocarditis has changed significantly over the past two decades. ### The Changing Landscape of Viral Causes Because the ability to diagnose viral infection has improved with molecular biology techniques, case reports and series have now associated DCM with **about 20 different viruses**. The evolution of viral causes over time is notable: - **1948–1950s:** Coxsackievirus B and other enteroviruses were the dominant causes - **1990s:** Adenovirus became more prevalent as enterovirus cases decreased - **2000–2007:** Parvovirus B19 became the most commonly detected viral genome; hepatitis C virus, human herpesvirus 6, and Epstein-Barr virus were also identified Seroepidemiological studies have linked enteroviruses to myocarditis through the co-occurrence of increased enterovirus antibody titers and a clinical syndrome of acute heart failure. In rare cases, viruses have been cultured directly from the heart tissue of patients with fatal acute myocarditis. However, whether parvovirus B19 is merely incidental or actually pathogenic in acute myocarditis remains unclear. Hepatitis C virus has been associated with myocarditis in Japan, while influenza virus, cytomegalovirus, and Epstein-Barr virus have been identified in some patients with both acute and chronic myocarditis. ### The Three Phases of Viral Cardiomyopathy The clinical spectrum of viral cardiomyopathy is classified as **fulminant** (sudden and severe), **acute**, or **chronic**. The disease progresses through three distinct phases: 1. **First phase (acute infection):** Viremia (virus in the bloodstream) is followed by infection of cardiomyocytes. This results in myocyte death and activation of the innate immune response, including interferon gamma, natural killer cells, and nitric oxide. 1. **Second phase (adaptive immune response):** Antigen-presenting cells engulf viral particles and cardiac proteins, then migrate to regional lymph nodes. In a subset of patients, antibodies to viral proteins—and to some cardiac proteins, including cardiac myosin and β or muscarinic receptors—are produced, and effector T cells multiply. 1. **Third phase (chronic phase):** The immune response is down-regulated, and fibrosis (scarring) replaces the cellular infiltrate in the myocardium. Under neurohumoral stimulation and hemodynamic stress, the ventricles dilate, leading to chronic cardiomyopathy. In this phase, viral genome may persist in the heart, or inflammatory mechanisms may persist, both contributing to ventricular dysfunction. ## Symptoms and Diagnosis: What Patients Should Know The clinical presentation of viral myocarditis varies widely—from nonspecific ECG abnormalities and mild viral illness to acute hemodynamic compromise or sudden cardiac death. However, **most patients are asymptomatic**, which makes the disease particularly challenging to detect. When symptoms do occur, data from the European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases provide useful insight. Among patients with myocarditis: - **72%** experienced dyspnea (shortness of breath) - **32%** had chest pain - **18%** had arrhythmias (abnormal heart rhythms) Some patients with acute focal myocarditis experience symptoms that mimic a heart attack, including acute onset of chest pain, tachyarrhythmia (fast heart rhythm), or sudden death. ### Physical Examination Findings Physical examination findings are variable but can provide important clues. They may include: - Tachycardia (rapid heart rate) - Laterally displaced point of maximal impulse (a sign of an enlarged heart) - Soft S1 sounds, or S3 or S4 gallop (abnormal heart sounds) - Lymphadenopathy (swollen lymph nodes, suggesting sarcoidosis) - Rash (suggesting a hypersensitivity reaction) - Polyarthritis (joint inflammation) - Subcutaneous nodules or erythema marginatum (a skin rash associated with acute rheumatic fever) ### Laboratory Testing Levels of cardiac biomarkers—including CK-MB, troponin I, and troponin T—are elevated in a minority of cases, indicating myocardial damage. However, one study found that only **35% of patients with suspected myocarditis had elevated troponin levels**, providing a sensitivity of **53%**. The serum concentration of troponin I is increased more frequently than CK-MB fractions in patients with acute myocarditis. Electrocardiography (ECG) may show nonspecific ST-T wave changes, ST-segment elevation mimicking acute myocardial infarction, or various degrees of atrioventricular node blockade. The presence of Q waves or bundle branch block is associated with increased rates of heart transplant or death. ### Echocardiography Echocardiography is an essential component of the diagnostic work-up to establish left ventricular (LV) function and rule out other causes of heart failure, such as valvular, congenital, or amyloid heart disease. Classic findings include global hypokinesis with or without pericardial effusion. Echocardiographic features can also help identify a fulminant course. A study by Felker and colleagues developed criteria to differentiate between fulminant and acute myocarditis. Patients with fulminant myocarditis had near-normal LV diastolic dimensions, and increased septal thickness at presentation was thought to be secondary to acute myocardial edema. Additionally, **right ventricular systolic function was found to be an independent predictor of death or myocardial transplant** in patients with acute myocarditis. Coronary angiography usually reveals normal coronary arteries, although it is important to note that myocarditis can also affect patients who have underlying coronary artery disease. ## Advanced Imaging: The Role of Cardiac MRI Recent advances in the diagnosis of myocarditis have centered on newer technologies to more precisely identify cardiac inflammation. The importance of noninvasive cardiac imaging stems from the low sensitivity of traditional histologic techniques. To diagnose myocarditis with **80% sensitivity**, an estimated **17 endomyocardial biopsies** are necessary—a fact that has led many experts to conclude there is a real need for practical noninvasive imaging studies. Cardiac MRI can be useful for diagnosing myocarditis by detecting edema (swelling), hyperemia (excess blood flow), or fibrosis (scarring) using sensitive sequences. A study by Friedrich and colleagues concluded that cardiovascular MRI shows promise in diagnosing myocarditis and demonstrated an evolution of contrast enhancement from focal to disseminated disease during a 2-week period. Newer techniques, including segmented inversion recovery gradient-echo sequences, have improved contrast enhancement of the myocardium and allow visualization of small myocardial injuries, increasing the sensitivity for detecting active myocarditis. Key study findings on cardiac MRI include: - In a study of **32 patients** with suspected myocarditis by Mahrholdt and colleagues, contrast enhancement was present in **88% of patients**, and biopsy samples from the area of enhancement showed active acute or chronic myocarditis in **90% of patients**. Focal myocardial gadolinium enhancement combined with regional wall motion abnormalities on echocardiography yielded a **positive predictive value of 71%** and a **negative predictive value of 100%**. - In a study by Yelgec and colleagues involving **20 patients** with suspected myocarditis, 5 patients underwent endomyocardial biopsy that showed normal findings, yet subsequent contrast-enhanced cardiac MRI revealed evidence of active myocarditis. This illustrates the potential of cardiac MRI to identify regions of myocarditis and increase the sensitivity of subsequent biopsy. ## Endomyocardial Biopsy: When Is It Needed? Histologic examination of heart tissue is required to confirm a diagnosis of myocarditis. However, the utility of endomyocardial biopsy is limited by sampling error—because inflammatory infiltrates can be patchy, a biopsy needle may miss the affected area. There is also variability in how pathologists interpret the specimens. In a large case series, the **sensitivity of endomyocardial biopsy was only 35%** compared to a clinical criterion standard that included recovery of myocardial function. However, immunostains for cell-specific markers such as T lymphocytes (CD3), macrophages (CD68), or human leukocyte antigens have a **sensitivity of up to 50%**, which is much better than routine histologic techniques. A recent case series suggests that the presence of inflammation as defined by immunoperoxidase stains may predict the subsequent risk of death or heart transplant. The presence of viral genomes in heart tissue from patients with acute myocarditis may also predict adverse events. Conversely, the **absence of viral genomes in patients with chronic myocarditis may identify a subset who will respond to a short course of immunosuppression**. The current recommendations from the American College of Cardiology Foundation/American Heart Association/European Society of Cardiology (ACCF/AHA/ESC) scientific statement support a limited role for endomyocardial biopsy. The **Class I indications** (situations where the procedure is recommended) are limited to: 1. Patients with new-onset heart failure of **less than 2 weeks** duration associated with a normal or dilated left ventricle with hemodynamic compromise 1. Patients with new-onset heart failure of **2 weeks to 3 months** duration with a dilated left ventricle, ventricular arrhythmia, or high-degree atrioventricular blockade 1. Patients whose condition fails to respond to treatment within 1 to 2 weeks ## Treatment Options for Viral Myocarditis The treatment of viral myocarditis varies by clinical presentation. Acute heart failure should be managed according to the current guidelines of the ACCF/AHA/ESC and the Heart Failure Society of America. Experimental models of murine myocarditis generally support the guideline-based treatment recommendations that apply to noninflammatory DCM. For hemodynamically stable patients with DCM and symptomatic heart failure, the following medications may be beneficial: - **Angiotensin-converting enzyme (ACE) inhibitors** or **angiotensin receptor blockers**: These medications relax blood vessels, reduce blood pressure, and decrease the workload on the heart. - **β-adrenergic blockers (β-blockers)**: In euvolemic patients (those with normal fluid volume), β-blockade may improve LV function, heart failure symptoms, and decrease inflammation. - **Aldosterone antagonists** (eplerenone or spironolactone): For patients who have persistent heart failure symptoms despite optimal management with angiotensin and adrenergic pathway inhibition. - **Diuretics**: Used to optimize intravascular volume and relieve fluid overload. - **Anticoagulation**: The use of blood thinners is similar to that in patients with nonischemic DCM, and is usually indicated in the setting of concomitant atrial fibrillation or arterial or venous thromboembolism. In patients with severe myocarditis and symptomatic hypotension (low blood pressure causing symptoms), parenteral (intravenous) inotropes may be required. These include: - **Phosphodiesterase inhibitors** (eg, milrinone) - **Adrenergic agonists** (eg, dobutamine or dopamine) ## Mechanical Circulatory Support for Severe Cases Despite maximal oral and parenteral medical therapy, some patients with acute myocarditis require mechanical circulatory support. Data from case series suggest that **ventricular assist devices (VADs)** may provide a bridge to transplant or to recovery in patients with acute myocarditis. **Extracorporeal membrane oxygenation (ECMO)** has also been used as a short-term bridge to transplant or recovery, but usually in patients with sustained ventricular arrhythmias, in whom support with ventricular assist devices would be less effective. In one case series by Chen and colleagues, **80% of patients who received ECMO therapy were bridged to recovery**. ## Antiviral and Immunosuppressive Therapy Because patients generally present days to weeks after the initial viral infection, **antiviral therapy has limited applicability in patients with acute viral myocarditis**. Additionally, the sensitivity of endomyocardial biopsy for detecting viral genomes in the myocardium has not been fully established. Nonetheless, antiviral agents have been evaluated in animal models and in a few small case series. Ribavirin and interferon alpha improved survival in mice with acute myocarditis when administered at the time of virus inoculation. However, **antiviral therapy cannot currently be recommended for the treatment of acute myocarditis**. The role of antiviral therapy for more chronic myocarditis associated with persistent viral genomes is an area of active clinical investigation. ### Immunosuppression: A Nuanced Picture A large body of experimental evidence suggests that acute and some chronic myocardial injury in myocarditis is due to an immune response involving T lymphocytes and autoreactive antibodies. However, data from the few randomized clinical trials suggest that, on average, patients with acute myocarditis do not benefit from immunosuppression. The **US Myocarditis Treatment Trial** is particularly instructive. In this study, **111 patients** with histologically confirmed myocarditis were randomly assigned to receive either placebo or prednisone combined with either azathioprine or cyclosporine. The results showed **no benefit in either transplant-free survival or change in LVEF** for the immunosuppression group. However, the duration of symptoms appears to be a major determinant of response to immunotherapy. A recent meta-analysis of immunosuppression and immunomodulation trials suggested that: - A symptom duration of **less than 6 months** was associated with a lack of active treatment benefit - Trials of DCM in which patients had symptoms for **more than 6 months** were generally positive The difference in response was largely due to spontaneous improvement in the placebo-arm participants who had symptoms for less than 6 months. In a trial of immunosuppression in patients with myocarditis and symptoms lasting more than 6 months, researchers found that persistence of viral genome leads to chronic inflammation, thus diminishing the recovery of LV function. ## Prognosis: What to Expect Important prognostic variables in viral myocarditis include the degree of left and right ventricular dysfunction, the presence of heart block, and specific histopathological forms of myocarditis. The degree of LV dysfunction at presentation is a strong predictor of outcomes. Right ventricular systolic function has also been identified as an independent predictor of death or myocardial transplant. Patients with fulminant myocarditis—despite appearing critically ill at presentation—often have a surprisingly good long-term prognosis when treated with aggressive hemodynamic support. Several mechanisms have been identified to explain why fulminant myocarditis results in persistent LV dysfunction less frequently than acute nonfulminant myocarditis. Kühl and colleagues postulated that persistence of viral genome leads to chronic inflammation, diminishing the recovery of LV function. The case report illustrates this well: the 19-year-old patient presented with an LVEF of just 15% to 20%, required mechanical ventilation and inotropic support, yet achieved a normal LVEF of 66% within 6 weeks—a testament to the potential for remarkable recovery in young patients with viral myocarditis. ## Study Limitations This review has several important limitations that patients should understand. First, the article was published in 2009, and while the core principles remain relevant, diagnostic techniques and treatment options have continued to evolve since that time. Second, the authors note that the exact incidence of myocarditis is difficult to ascertain, and many cases go undiagnosed because patients are asymptomatic. Third, the pathogenesis data come largely from animal models, which may not perfectly reflect human disease. Fourth, randomized clinical trial data on immunosuppression are limited, and the trials that exist have relatively small sample sizes. Finally, whether certain viruses detected in heart tissue (particularly parvovirus B19) are truly pathogenic or merely incidental remains unclear, which complicates both diagnosis and treatment decisions. ## Recommendations for Patients Based on this review, here are key points patients should discuss with their healthcare providers: 1. **Seek prompt evaluation for persistent symptoms:** If you have recently had a viral infection and develop shortness of breath, chest pain, palpitations, or unusual fatigue, seek medical attention promptly. Symptom duration matters—it influences both diagnosis and treatment response. 1. **Understand the diagnostic process:** Diagnosis often involves a combination of blood tests (troponin, CK-MB), ECG, echocardiography, cardiac MRI, and in specific situations, endomyocardial biopsy. Not every patient needs every test. 1. **Know when biopsy is warranted:** Endomyocardial biopsy is recommended for patients with new-onset heart failure of less than 2 weeks with hemodynamic compromise, new-onset heart failure of 2 weeks to 3 months with a dilated left ventricle, ventricular arrhythmia, or high-degree heart block, or when the condition fails to respond to 1 to 2 weeks of standard treatment. 1. **Follow heart failure treatment guidelines:** Standard heart failure medications—ACE inhibitors, angiotensin receptor blockers, β-blockers, aldosterone antagonists, and diuretics—remain the cornerstone of treatment for stable patients. 1. **Be aware that recovery is possible:** Even patients with severely reduced heart function can recover substantially, as demonstrated by the case report. The 19-year-old patient's LVEF improved from 15–20% to 66% within 6 weeks. 1. **Ask about clinical trials:** The role of antiviral therapy for chronic myocarditis with persistent viral genomes is an active area of investigation. Patients with chronic symptoms may wish to discuss clinical trial options with their cardiologist. ## Frequently Asked Questions ### What is myocarditis and why is it sometimes not diagnosed? Myocarditis is inflammation of the heart muscle. It can weaken and enlarge the heart, leading to dilated cardiomyopathy. Many cases go undiagnosed because symptoms can be vague or absent. It is an important worldwide cause of heart failure and can be found in up to 9% of routine autopsies. ### What symptoms should I watch for after a viral infection? In one European study of patients with myocarditis, 72% had shortness of breath, 32% had chest pain, and 18% had abnormal heart rhythms. Some people have no symptoms at all. If you recently had a viral illness and develop these symptoms, seek medical attention promptly. ### How do doctors diagnose myocarditis? Diagnosis may involve blood tests for troponin and CK-MB, an ECG, an echocardiogram, cardiac MRI, and sometimes a biopsy of heart tissue. However, in one study only 35% of patients with suspected myocarditis had elevated troponin levels, so normal blood tests do not rule it out. ### When is a heart biopsy needed for myocarditis? Biopsy is recommended for patients with new-onset heart failure lasting less than 2 weeks with hemodynamic compromise, or heart failure of 2 weeks to 3 months with a dilated left ventricle, ventricular arrhythmia, or high-degree heart block. It is also considered if heart failure fails to respond to 1–2 weeks of treatment. ### What are the main treatments for viral myocarditis? For stable patients, standard heart failure medications are used: ACE inhibitors, beta-blockers, aldosterone antagonists, and diuretics. For severe cases, intravenous inotropes may be needed. Mechanical support like ventricular assist devices or ECMO can serve as a bridge to recovery or transplant. Antiviral therapy is not currently recommended for acute myocarditis. ### Can the heart recover from severe viral myocarditis? Yes, recovery is possible even when heart function is severely reduced. In one case, a 19-year-old woman had a left ventricular ejection fraction of only 15–20% and needed breathing support, yet her heart function returned to a normal 66% within 6 weeks. But prognosis varies based on how severe the heart dysfunction is at diagnosis. ### When should a patient with suspected or confirmed viral myocarditis seek a second opinion? A second opinion is valuable if your diagnosis is uncertain, especially if symptoms are vague or test results are inconclusive. Since myocarditis can mimic a heart attack and troponin levels are normal in many patients, expert review of cardiac MRI and biopsy findings may clarify the diagnosis. If your heart function does not improve after 1-2 weeks of standard heart failure treatment, or if you are considering immunosuppressive therapy or mechanical circulatory support, a second opinion can help confirm the treatment plan. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information **Original Article Title:** Diagnosis and Treatment of Viral Myocarditis **Authors:** Jason C. Schultz, MD; Anthony A. Hilliard, MD; Leslie T. Cooper Jr, MD; and Charanjit S. Rihal, MD **Publication:** Mayo Clinic Proceedings, November 2009;84(11):1001-1009. Published by the Mayo Foundation for Medical Education and Research. **Affiliation:** Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. Dr. Schultz is now with the University of Minnesota, Minneapolis. **Note:** This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace professional medical advice. Patients with questions about myocarditis should consult their healthcare provider. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/understanding-viral-myocarditis-a-complete-guide-to-diagnosis-and-treatment